Prime Capital Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.6M | Buy |
131,500
+1,882
| +1% | +$417K | 0.33% | 75 |
|
|
2025
Q4 | $29.6M | Buy |
129,618
+1,028
| +0.8% | +$234K | 0.36% | 56 |
|
|
2025
Q3 | $29.8M | Buy |
128,590
+3,759
| +3% | +$765K | 0.37% | 54 |
|
|
2025
Q2 | $23.2M | Sell |
124,831
-30,567
| -20% | -$5.68M | 0.31% | 64 |
|
|
2025
Q1 | $32.6M | Buy |
155,398
+28,578
| +23% | +$5.56M | 0.38% | 58 |
|
|
2024
Q4 | $22.5M | Sell |
126,820
-7,704
| -6% | -$1.42M | 0.33% | 58 |
|
|
2024
Q3 | $26.6M | Sell |
134,524
-44,239
| -25% | -$8.26M | 0.38% | 56 |
|
|
2024
Q2 | $30.7M | Sell |
178,763
-35,405
| -17% | -$5.86M | 0.45% | 51 |
|
|
2024
Q1 | $39M | Buy |
214,168
+12,982
| +6% | +$2.24M | 0.54% | 38 |
|
|
2023
Q4 | $31.2M | Buy |
201,186
+19,033
| +10% | +$2.77M | 0.47% | 48 |
|
|
2023
Q3 | $27.2M | Sell |
182,153
-17,919
| -9% | -$2.63M | 0.56% | 41 |
|
|
2023
Q2 | $27M | Buy |
200,072
+84,592
| +73% | +$12.4M | 0.53% | 45 |
|
|
2023
Q1 | $18.4M | Sell |
115,480
-60,687
| -34% | -$9.28M | 0.76% | 28 |
|
|
2022
Q4 | $28.5M | Buy |
176,167
+84,290
| +92% | +$12.9M | 1.08% | 20 |
|
|
2022
Q3 | $12.3M | Buy |
91,877
+28,662
| +45% | +$4.11M | 0.71% | 28 |
|
|
2022
Q2 | $9.68M | Buy |
63,215
+14,154
| +29% | +$2.16M | 0.58% | 29 |
|
|
2022
Q1 | $6.64M | Sell |
49,061
-5,076
| -9% | -$737K | 0.37% | 50 |
|
|
2021
Q4 | $7.33M | Buy |
54,137
+9,742
| +22% | +$1.15M | 0.39% | 47 |
|
|
2021
Q3 | $4.79M | Buy |
44,395
+6,806
| +18% | +$778K | 0.3% | 64 |
|
|
2021
Q2 | $4.23M | Buy |
37,589
+3,943
| +12% | +$444K | 0.25% | 87 |
|
|
2021
Q1 | $3.64M | Sell |
33,646
-12,398
| -27% | -$1.33M | 0.26% | 82 |
|
|
2020
Q4 | $4.93M | Sell |
46,044
-45,410
| -50% | -$4.36M | 0.38% | 40 |
|
|
2020
Q3 | $8.01M | Buy |
91,454
+18,042
| +25% | +$1.7M | 0.67% | 18 |
|
|
2020
Q2 | $7.21M | Buy |
73,412
+21,841
| +42% | +$1.92M | 0.68% | 19 |
|
|
2020
Q1 | $3.93M | Buy |
51,571
+2,453
| +5% | +$209K | 0.47% | 39 |
|
|
2019
Q4 | $4.35M | Sell |
49,118
-38,267
| -44% | -$3.18M | 0.5% | 38 |
|
|
2019
Q3 | $6.62M | Buy |
87,385
+50,088
| +134% | +$3.43M | 1.02% | 19 |
|
|
2019
Q2 | $2.71M | Buy |
37,297
+32,250
| +639% | +$2.53M | 0.49% | 53 |
|
|
2019
Q1 | $407K | Buy |
5,047
+4,755
| +1,628% | +$389K | 0.12% | 107 |
|
|
2018
Q4 | $27K | Buy |
+292
| New | +$25.7K | 0.01% | 190 |
|
|
2018
Q3 | – | Sell |
-50
| Closed | -$5K | – | 256 |
|
|
2018
Q2 | $5K | Hold |
50
| – | – | ﹤0.01% | 286 |
|
|
2018
Q1 | $5K | Hold |
50
| – | – | ﹤0.01% | 221 |
|
|
2017
Q4 | $5K | Buy |
+50
| New | +$4.71K | ﹤0.01% | 207 |
|
Other funds holding ABBV
VCM
VPM
Prime Capital Investment Advisors's ABBV Position: Q1 2026 in Review
Prime Capital Investment Advisors increased its AbbVie (ABBV) stake by 1.5% in Q1 2026, buying an estimated $417K and bringing the position to 131,500 shares worth $28.6M. The position accounts for 0.33% of the portfolio, ranked #75.
Prime Capital Investment Advisors first reported a position in ABBV in Q4 2017 and has held it in 33 quarters since. The position peaked at $39M in Q1 2024. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Prime Capital Investment Advisors held 131,500 shares of AbbVie worth $28.6M as of Q1 2026.
- Prime Capital Investment Advisors bought 1,882 AbbVie shares in Q1 2026, an estimated $417K.
- AbbVie made up 0.33% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #75 holding.
- Prime Capital Investment Advisors first reported a position in AbbVie in Q4 2017 and has held it in 33 quarters since.
- Prime Capital Investment Advisors's AbbVie position peaked at $39M in Q1 2024.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.